Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
XORTX Therapeutics Inc ( (TSE:XRTX) ) has issued an announcement.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company specializing in treatments for gout and kidney-related diseases, is advancing a portfolio of uric acid–targeting drug candidates, including late-stage programs for gout, ADPKD, and acute organ injury related to respiratory infections, as well as a preclinical therapy for diabetic nephropathy.
The company will consolidate its common shares on a one-for-five basis effective March 27, 2026, reducing its outstanding share count from about 6.96 million to roughly 1.39 million, with fractional shares rounded rather than paid in cash. The move, already cleared by the TSX Venture Exchange and supported by shareholders, is aimed at lifting and maintaining the Nasdaq trading price above the US$1 threshold to preserve the stock’s continued listing, a key consideration for the firm’s market visibility and access to capital.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.61 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on XRTX Stock
According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease. Its pipeline includes three clinically advanced programs—XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, and XRx-101 for acute kidney and other organ injury linked to respiratory virus infections, alongside a preclinical program, XRx-225, targeting type 2 diabetic nephropathy.
Average Trading Volume: 5,476
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.46M
See more data about XRTX stock on TipRanks’ Stock Analysis page.